Loading...
•
Sep 30, 2022
Castle Biosciences Q3 2022 Earnings Report
Achieved strong top-line growth and a new record in total quarterly test report volume.
Key Takeaways
Castle Biosciences announced strong Q3 2022 results, with revenue growing by 58% compared to Q3 2021, reaching $37.0 million. The company delivered 12,114 total test reports, a 57% increase over the same period last year. They are increasing 2022 revenue guidance to $132-137 million.
Q3 2022 revenue grew by 58% over Q3 2021 to $37.0 million.
Delivered 12,114 total test reports in Q3 2022, an increase of 57% compared to Q3 2021.
Foundational guideposts and three-year financial targets presented at Investor Day in September.
Further increasing 2022 revenue guidance to $132-137 million from $130-135 million.
Forward Guidance
Castle Biosciences is increasing its guidance for anticipated total revenue in 2022. The Company now anticipates generating $132-137 million in total revenue in 2022, compared to the previously provided guidance of $130-135 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...